

Effectiveness of an inactivated virus-based SARS-CoV-2 test-negative, case-control study

Lancet Infectious Diseases, The
22, 349-356

DOI: [10.1016/s1473-3099\(21\)00674-5](https://doi.org/10.1016/s1473-3099(21)00674-5)

Citation Report

#	ARTICLE	IF	CITATIONS
2	SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 301-302.	9.1	17
4	SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. <i>JAMA Network Open</i> , 2022, 5, e2142210.	5.9	48
9	Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population. <i>Journal of Medical Virology</i> , 2022, , .	5.0	16
10	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	2.3	21
12	Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study. <i>Vaccines</i> , 2021, 9, 1461.	4.4	58
13	Microbiology in India: Status, Challenges, and Scope. <i>Environmental Microbiology</i> , 2022, , .	3.8	0
14	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	62
15	Relationship between blood clots and COVID-19 vaccines: A literature review. <i>Open Life Sciences</i> , 2022, 17, 401-415.	1.4	6
16	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
17	A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys. <i>Computers in Biology and Medicine</i> , 2022, 146, 105419.	7.0	8
19	SARS-CoV-2 Non Responders - An Analysis of Non Responsiveness to SARS-CoV-2 Vaccines among Healthcare Workers in 2021. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.9	2
20	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ</i> , The, 0, , e069989.	6.0	78
21	Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6083.	4.1	10
22	Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	25
23	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	4.4	1
24	Antigenicity of genomic epidemiology concerning viral evolution and vaccine efficacy for SARS-COV-2- A review. , 2022, , .		0
25	Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination. <i>Nature Communications</i> , 2022, 13, .	12.8	11
26	Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2â€“18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1303-1312.	9.1	26

#	ARTICLE	IF	CITATIONS
27	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. <i>Scientific Reports</i> , 2022, 12, .	3.3	23
28	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	4.0	19
29	Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India. <i>Vaccines</i> , 2022, 10, 1153.	4.4	11
30	Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study. , 2022, 10, 251513552211150.	2.3	0
31	Inactivated vaccine Covaxin/BBV152: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	19
32	Metabolomics-based investigation of SARS-CoV-2 vaccination (Sinovac) reveals an immune-dependent metabolite biomarker. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
33	Need for focused pharmacovigilance in the face of rapid COVID-19 vaccine development. <i>Current Drug Safety</i> , 2022, 17, .	0.6	0
34	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	1.1	0
35	Efficacy of Bacillus Calmetteâ€“GuÃ©rin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2205-2217.	4.0	22
37	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	4.4	10
39	Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon. <i>PLoS ONE</i> , 2022, 17, e0274829.	2.5	1
40	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	6.9	5
43	Reduced antibody response to COVID-19 vaccine composed of inactivated SARS-CoV-2 in diabetic individuals. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	8
44	Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: A retrospective cohort study from the National COVID Cohort Collaborative. <i>PLoS ONE</i> , 2023, 18, e0279968.	2.5	2
45	Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative caseâ€“control study. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	0
46	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>iScience</i> , 2023, 26, 105949.	4.1	1
47	The risk of adverse cardiovascular complications following covid-19 vaccination. <i>Pharmacy & Pharmacology International Journal</i> , 2023, 11, 10-13.	0.2	0
48	COVID-19 Vaccinesâ€“All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	2.1	4

#	ARTICLE	IF	CITATIONS
49	A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases. <i>British Journal of Dermatology</i> , 2023, 188, 268-277.	1.5	4
50	Association of Lower Antispikes Antibody Levels with Mortality in ICU Patients with COVID-19 Disease. <i>Critical Care Research and Practice</i> , 2023, 2023, 1-8.	1.1	0
51	A community-based study on willingness and predictors to receive precautionary dose of COVID-19 vaccine in Puducherry. <i>International Journal of Academic Medicine</i> , 2023, 9, 4.	0.2	0
52	COVID Vaccines vs. Viral Evolution: Who Will Win the Battle?. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, .	1.1	0
53	Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study. <i>Vaccines</i> , 2023, 11, 826.	4.4	5
55	Late occurrence of ChAdOx1 vaccine-induced myocarditis presenting with ventricular arrhythmia. <i>Case Reports International</i> , 2023, 12, 18-22.	0.0	0
56	Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India. <i>Drug Safety</i> , 2023, 46, 553-563.	3.2	3
58	Efficacy of COVID-19 Vaccines against Mortality among COVID-19 Cases of Indore, Central India. <i>Indian Journal of Respiratory Care</i> , 2023, 12, 59-61.	0.1	0
59	Longitudinal clinical phenotyping of post COVID condition in Mexican adults recovering from severe COVID-19: a prospective cohort study. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
60	Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study. <i>EClinicalMedicine</i> , 2023, 64, 102168.	7.1	1
61	Efficacy of a bivalent (D614+B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2023, 11, 975-990.	10.7	3
62	Evaluation of PastroCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine. <i>Heliyon</i> , 2023, 9, e20555.	3.2	6
63	Strengthening and Expanding Laboratories for Aetiological Diagnosis in Pandemics: Lessons from the Indian SARS-CoV-2 Experience. , 2023, , 163-173.		0
64	COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type. <i>Viruses</i> , 2023, 15, 2181.	3.3	1
65	Populist Protests and the Dynamic Zero-COVID Policy: (Re)emerging Pragmatic Populism in China. <i>International Studies</i> , 0, , .	0.8	0
66	Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review. <i>Vaccine</i> , 2024, 42, 995-1003.	3.8	0
67	Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
68	Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine. <i>Expert Review of Vaccines</i> , 2024, 23, 283-293.	4.4	0